Methodologies for conducting trials and other studies, including data handling and analysis at ESTRO-EORTC workshop
26 Apr 2017
The EORTC contributes to ESTRO 36, Europe’s largest conference in radiation oncology in Vienna, Austria on Friday, May 5th with a pre-congress course/workshop which will be held from 13.30 – 18.00 in Galleria 11-12.
The workshop will be chaired by Denis Lacombe (EORTC Director General) and Vincent Grégoire (Chair of the Head and Neck Group and member of the Radiation Oncology Group).
Our workshop offers the opportunity to learn from experts about current views on conducting radiation oncology studies as well as data handling and analysis, building from the past into the future.
Laurence Collette (Belgium), an expert in statistics, clinical trials and epidemiology will explain the specificities of radiotherapy studies; which designs and endpoints are preferably used or not.
Michael Baumann (Germany), a radiation oncologist specialized in thoracic tumours, head & neck cancer, and translational radiation oncology will talk about studies with new radiation technologies.
Eric Deutsch (France), Head of the Radiotherapy Department of Gustave Roussy Cancer Campus in Paris, will detail the methodological aspects of studies using the combination of medication and radiation.
After the break, recycling of old studies will be discussed. It will be explained how data from the past can be used to inform about current treatments:
Maja Maraldo (Denmark), a resident in clinical oncology, will illustrate this by means of her experience in lymphoma.
Mirjam Mast (The Netherlands), experienced in research & development in radiotherapy, will share her experience in early breast cancer.
Conny Vrieling (Switzerland), a radiation oncologist, will talk about the outcome after first local failure in early breast cancer, in long-term survivors of radiation.
This session will be closed with a discussion with all speakers.
Related News
EORTC: Advancing research and treatment for rare cancers
29 Feb 2024
EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration
22 Feb 2024
Appointment of Malte Peters as EORTC Strategic Alliance Officer
9 Feb 2024
Unique series of workshops in partnership with the European Medicines Agency (EMA)
7 Feb 2024
EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)
14 Dec 2023
Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023
6 Dec 2023
EORTC Quality of Life measures integrated in CDISC
20 Nov 2023
EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma
7 Nov 2023
Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia
31 Oct 2023
New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023
20 Oct 2023